Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 12;12:972215. doi: 10.3389/fonc.2022.972215

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Han, Wang, Chang, Hu, Liang, Li, Liu, He, Yang and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Prognostic value of ICI therapy. (A, B) Sizes of training cohort responses, non-response sample GRGPIs, and TMB values. (C, D) Differences in GRGPIs and TMB between responsive and non-responsive samples from IMvigor210. (E) Proportions of immunotherapy-responsive and non-responsive samples in the three subgroups from the IMvigor210 cohort. (F) ROC curves of GRGPI, TMB, and GRGPI combined with TMB in the IMvigor210 cohort. Analysis of drug sensitivity. Differences in IC50 values of (G) Gefitinib, (H) Erlotinib, and (I) Cisplatin in the high-GRGPI group and low-GRGPI group.